3 Macular Degeneration Clinical Trials in Springdale, AR (2026)

Q: How do I join a clinical trial in Springdale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you.

Recruiting Macular Degeneration Studies in Springdale

NCT06541704Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (...

Springdale, AR975 participantsRegeneron Pharmaceuticals

View Study Details

NCT07440225Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person...

Springdale, AR960 participantsEyeBiotech Ltd.

View Study Details

NCT07482176Recruiting

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-...

Springdale, AR284 participantsAdverum Biotechnologies, Inc.

View Study Details

About Macular Degeneration Clinical Trials in Springdale

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.

There are currently 3 macular degeneration clinical trials recruiting participants in Springdale, AR. These studies are seeking a combined 2,219 participants. Research is being sponsored by Regeneron Pharmaceuticals, EyeBiotech Ltd., Adverum Biotechnologies, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Macular Degeneration Clinical Trials in Springdale — FAQ

Are there macular degeneration clinical trials in Springdale?

Yes, there are 3 macular degeneration clinical trials currently recruiting in Springdale, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Springdale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Springdale research site will contact you about next steps.

Are clinical trials in Springdale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Springdale studies also compensate for your time and travel.

What macular degeneration treatments are being tested?

The 3 active trials in Springdale are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.

Data updated July 13, 2026 from ClinicalTrials.gov